Market requirements · LV
Latvia
The ZVA regulates under the Farmacijas likums and has published dated GLP-1 safety communications. No peptide-specific position was located.
| Tell us the compounds you need for Latvia. | Ask about Latvia |
The regime
How compounds are classified in Latvia
| Governing law and regulator | Medicines in Latvia are regulated under the Farmacijas likums (Pharmacy Law) and related Cabinet of Ministers regulations, enforced by the Zalu valsts agentura (ZVA), the State Medicines Agency, working alongside the Veselibas inspekcija (Health Inspectorate) on illegal sales. |
|---|---|
| Applicable position | The general medicines framework applies, administered by the ZVA. Classification follows the compound and its presentation. |
| GLP-1 class | ZVA has published dated safety communications on GLP-1 receptor agonists, including a 17 July 2023 notice on Ozempic, Wegovy and Saxenda covering a self-harm/suicidal-ideation signal evaluation, plus separate guidance on ensuring GLP-1 availability amid supply pressure and off-label weight-loss demand. |
| Prescription-only compounds | Somatropin and gonadotropin medicines require a prescription under Latvia's medicines register administered by ZVA; Melanotan II has no marketing authorisation and no ZVA statement naming it was found. |
| Enforcement posture | ZVA and the Health Inspectorate jointly urge residents not to buy medicines from illegal websites or social media, pointing to the EU common logo as the marker of a legitimate online pharmacy; no peptide- or GLP-1-specific seizure figures were found on either agency's site. |
| Already supplying Latvia? Send the compounds and volumes you buy today and we will quote against them. | Send your list |
Your obligations
What a buyer in Latvia needs settled
- Apply to ZVA for a vairumtirdzniecibas atlauja (wholesale distribution licence) before importing or reselling medicinal products, meeting ZVA's premises, GDP and responsible-person requirements.
- Do not market a research-purposes label as a way around Latvian medicines law; ZVA has not published any such exemption.
- Handle GLP-1 products (semaglutide, tirzepatide) as actively monitored medicines given ZVA's ongoing dated safety-signal communications on the class.
- Assume somatropin and gonadotropins is prescription-only medicines requiring licensed pharmacy or wholesale distribution channels.
We will ask about this at enquiry. We check the authorisations your activity requires before quoting, and we confirm the position per compound rather than for the market as a whole.
Sources
Check this yourself
Every position above traces to a dated public document. The authority, the document, the date and the link are below.
| Authority and document | Date | Link |
|---|---|---|
| ZVA (Zalu valsts agentura) Verte diabeta un svara samazinasanas zales, tai skaita zales Ozempic, Wegovy un Saxenda | 2023-07-17 | www.zva.gov.lv/lv/jaunumi-un-publikacijas/jaunumi/verte-di... |
| ZVA Ieteikumi GLP-1 receptoru agonistu pieejamibas nodrosinasanai | undated | www.zva.gov.lv/lv/jaunumi-un-publikacijas/jaunumi/ieteikum... |
| Veselibas inspekcija (VI), referencing ZVA Aicina neiegadaties zales nelikumigas interneta vietnes un socialajos tiklos | undated | www.vi.gov.lv/lv/jaunums/aicina-neiegadaties-zales-nelikum... |
| ZVA Jauna lieltirgotava (new wholesaler - licensing guidance) | undated | www.zva.gov.lv/lv/industrijai/lieltirgotavas-un-brokeri/ja... |
Links go to the issuing body wherever one exists. Positions change. If you are relying on any of this, check the source rather than this page.
Market brief
Take the Latvia brief as a PDF
The regime, the buyer obligations and all 4 sources, dated and linked, in one document you can forward.
Nearby
Baltics and nearby markets
Buyers supplying one of these usually supply the others. The requirements are not the same.
| Code | Market | Sources | |
|---|---|---|---|
| LT | Lithuania | 4 sources | The VVKT regulates under the Farmacijos istatymas and requires a wholesale dis... |
| EE | Estonia | 2 sources | Ravimiamet published a dated statement in June 2026 addressing internet-sold p... |
| DE | Germany | 2 sources | Germany applies the Arzneimittelgesetz alongside anti-doping legislation, and ... |
Scope
How to use this page
A summary of the published regulatory position in Latvia as at 2026-08-20, written for procurement teams deciding how to source. Every source is dated and linked so it can be checked at origin.
It is not legal advice. Full terms of supply, including where responsibility sits, are set out in our terms of supply.
Questions
Supplying into Latvia
Do you supply into Latvia?
We supply businesses that hold the authorisations their activity requires. Whether a specific compound can be supplied into Latvia depends on that compound and on your authorisations, and we confirm it per compound at the enquiry stage.
Who carries the compliance obligation?
The importer of record and the party placing the product on the market, which is the buyer. We supply the batch documentation that supports your file. We cannot hold your authorisations for you.
How current is this page?
It was reviewed on 2026-08-20 and is scheduled for review again on 2026-11-18. Every source is dated and linked, so you can check the original.
We already supply into Latvia. What changes if we source from you?
The batch documentation. You receive a Certificate of Analysis per batch, which can be issued under your own brand. The import and market-placing responsibilities stay where they are.
Is this legal advice?
No. It is a summary of the regulatory positions those authorities have published, as at the review date above. Take advice in your own market before you rely on it.
Enquire about supply into Latvia
Tell us the compounds and your authorisations. We confirm per compound before anything ships.